| Autor: |
Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, Gomez ME, Peloquin C, Ashkin D, Goswami ND |
| Jazyk: |
angličtina |
| Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2021 Jan; Vol. 27 (1). Date of Electronic Publication: 2020 Nov 23. |
| DOI: |
10.3201/eid2701.203766 |
| Abstrakt: |
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
